TGTX - TG Therapeutics - Stock Price & Dividends

TG Therapeutics Inc. is a commercial-stage biopharmaceutical company that specializes in developing and commercializing innovative treatments for B-cell mediated diseases. The company's primary focus is on addressing unmet medical needs in the United States and globally.

One of its flagship products is BRIUMVI, an anti-CD20 monoclonal antibody designed to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This medication has the potential to significantly improve the quality of life for patients living with this debilitating condition.

TG Therapeutics has a robust development pipeline, featuring several promising candidates. Umbralisib, an oral inhibitor of PI3K-delta, is being developed to treat adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma. Another notable candidate is TG-1701, an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that has shown selectivity to BTK in vitro kinase screening. Additionally, the company is working on TG-1801, a bispecific CD47 and CD19 antibody.

Through strategic partnerships and collaborations, TG Therapeutics has established agreements with leading companies, including LFB Biotechnologies S.A.S, GTC Biotherapeutics, and Novimmune SA, to accelerate the development and commercialization of its investigational medicines. The company has also formed a collaboration agreement with Checkpoint Therapeutics, Inc. to develop and commercialize anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.

Founded in 1993, TG Therapeutics Inc. is headquartered in Morrisville, North Carolina, and is committed to advancing its research pipeline to bring innovative treatments to patients worldwide. For more information, please visit the company's website at https://www.tgtherapeutics.com.